Discovery of anticancer polymeric drugs that mimic the action of TRAIL

Informations projet

PolyDrug Discovery

N° de convention de subvention: 703466

DOI

10.3030/703466

Projet clôturé le 1 Janvier 2017

Date de signature de la CE 10 Février 2016

Date de début 1 Mars 2016

Date de fin 28 Février 2018

Financé au titre de

• EXCELLENT SCIENCE - Marie Skłodowska-Curie Actions

Coût total

€ 173 857,20

Contribution de l’UE

€ 173 857,20

Coordonné par

KAROLINSKA INSTITUTET
Sweden

Periodic Reporting for period 1 - PolyDrug Discovery (Discovery of anticancer polymeric drugs that mimic the action of TRAIL)

Période du rapport: 2016-03-01 au 2018-02-28

Résumé du contexte et des objectifs généraux du projet

The objective of this project was to develop a polymeric drug (PolyDrug) that mimics the activity of tumor necrosis factor-related apoptosis inducing ligand (TRAIL) for the treatment of breast cancer. Having such a polymeric and therefore synthetic replacement for this therapeutic would have tremendous benefits including greater drug stability and biodistribution. Therefore, this project outlined a two year plan to develop such a drug by following the standard drug discovery process.

Travail effectué depuis le début du projet jusqu’à la fin de la période considérée dans le rapport et principaux résultats atteints jusqu’à présent

While this fellowship is being terminated early, I have achieved the goals set out over this 10 month period. This progress is critical as I plan to continue this project in my lab at Rutgers University. I was successful in preparing a variety of death receptor targeting peptides and managed to select a few peptides with low nM affinity towards this receptor. This was a main objective of this first year and these peptides will move on to further evaluation in my new position. During this first year, I also optimized the technique for preparing the polymers and showed that we are able to make all drug variations needed for the drug discovery process. In parallel, I also developed the drug screening cell culture assay that is need to run the drug discovery process. This culmination of this work puts me on target with the fellowship in order to continue at Rutgers University.

Progrès au-delà de l’état des connaissances et impact potentiel prévu (y compris l’impact socio-économique et les conséquences sociétales plus larges du projet jusqu’à présent)

This project is ongoing in my new position and the expected impact is still to be determined. Hopefully in one years time (as originally outlined), we will have a better update on the overall impact of this research.

combinatorial-low-volume-synthesis-of-well-def.jpg